Observational studyAnnals of hematology2020

Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.

Jing Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.